세계의 비주사 인슐린 시장(2025년)

Non-injectable Insulin Global Market Report 2025

US $ 4,490 ￦ 6,496,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,390,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,284,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비주사 인슐린 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 10.1%로 31억 7,000만 달러로 성장할 것으로 예측됩니다. 예측 기간 중의 성장은 환자의 순응도에 대한 지속적인 관심, 바늘 공포증의 지속적인 해결, 삶의 질 향상, 지속적인 안전 강화, 감염 및 부상 위험 감소에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 기술 발전, 기술 솔루션의 진화, 디지털 헬스 통합, 나노 기술 적용, 병용 요법 등이 있습니다.

비만과 당뇨병 유병률 증가는 향후 수년간 비주사 인슐린 시장의 성장을 가속할 것으로 예상됩니다. 비만은 일반적으로 칼로리 섭취와 에너지 소비의 불균형으로 인해 체지방이 과도하게 축적되는 것으로 정의됩니다. 반면, 당뇨병은 장기간의 고혈당을 특징으로 하는 대사 장애의 집합체입니다. 비주사 인슐린은 인슐린 치료의 장벽을 극복하여 치료 순응도를 개선하고, 체중 조절에 도움을 줄 수 있으며, 보다 편리한 치료 옵션을 제공할 수 있으므로 당뇨병 및 비만 관리에 활용되고 있습니다. 예를 들어 2022년 스위스에 본부를 둔 NGO인 세계심장연맹(World Heart Federation)은 전 세계 비만율이 크게 증가할 것으로 예상되며, 2021년에는 어린이와 성인을 포함해 약 23억 명이 과체중과 비만에 직면하며, 이 수치는 2025년까지 27억 명으로 증가할 것으로 예상한다고 보고했습니다. 또한 영국에 기반을 둔 당뇨병 자선단체인 영국당뇨병협회의 2023년 4월 보고서에 따르면 영국에는 430만 명의 당뇨병 환자가 있으며, 240만 명 이상이 2형 당뇨병 발병 위험이 높으며, 2021-2022년 등록자 수는 전년 대비 14만 8,951명 증가할 것으로 예상했습니다. 증가하고 있습니다. 이처럼 비만과 당뇨병 문제의 심각성이 비주사 인슐린 시장의 성장을 가속하고 있습니다.

비주사형 인슐린 시장의 주요 기업은 여러 차례 인슐린 주사를 맞으며 당뇨병을 관리하는 환자들의 삶을 개선하기 위해 니들 프리 경구용 인슐린 스프레이와 같은 혁신적인 약물전달 기술에 집중하고 있습니다. 니들 프리 인슐린 스프레이는 혈당 조절을 위한 통증 없는 대안을 제공하고, 복용량을 입에 직접 분무할 수 있도록 함으로써 편리한 대안을 제공합니다. 예를 들어 NiedlFree Technologies는 2023년 11월 경구용 인슐린 스프레이인 오쥴린(Ozulin)을 발표했습니다. 오쥴린은 당뇨병 환자, 특히 기존 인슐린 주사법에 어려움을 겪는 환자들에게 사용하기 쉬운 솔루션을 제공하는 것을 목표로 하고 있습니다. 오쥴린은 인슐린 주사를 대체할 수 있는 보다 편리하고 고통스럽지 않은 방법을 제공함으로써 당뇨병 관리에 혁명을 일으킬 수 있을 것으로 기대됩니다.

세계의 비주사 인슐린 시장에 대해 조사했으며, 시장의 개요와 유형별, 유통 채널별, 유형별, 지역·국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 개요

제2장 비주사 인슐린 시장의 특징

제3장 비주사 인슐린 시장 동향과 전략

제4장 비주사 인슐린 시장 - 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 비주사 인슐린 성장 분석과 전략 분석 프레임워크

• 세계의 비주사 인슐린 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 용도 산업의 분석
• 세계의 비주사 인슐린 시장의 성장률 분석
• 세계의 비주사 인슐린 시장 규모 실적과 성장, 2019-2024년
• 세계의 비주사 인슐린 시장 규모와 성장 예측, 2024-2029년, 2034년 예상
• 세계의 비주사 인슐린 TAM(Total Addressable Market)

제6장 비주사 인슐린 시장 세분화

• 세계의 비주사 인슐린 시장, 유형별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 합성 인슐린
• 반합성 인슐린
• 세계의 비주사 인슐린 시장, 제품별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 정제
• 스프레이
• 기타
• 세계의 비주사 인슐린 시장, 유통 채널별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 온라인 약국
• 드러그스토어
• 세계의 비주사 인슐린 시장, 합성 인슐린의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 속효형 합성 인슐린
• 단시간 작용형 합성 인슐린
• 중간형 합성 인슐린
• 지속성 합성 인슐린
• 세계의 비주사 인슐린 시장, 반합성 인슐린의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
• 수식 인슐린 아날로그
• 복합 인슐린
• 바이오시밀러 인슐린
• 서방형 인슐린 제제

제7장 비주사 인슐린 시장의 지역별·국가별 분석

• 세계의 비주사 인슐린 시장, 지역별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
• 세계의 비주사 인슐린 시장, 국가별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측

제8장 아시아태평양의 비주사 인슐린 시장

제9장 중국의 비주사 인슐린 시장

제10장 인도의 비주사 인슐린 시장

제11장 일본의 비주사 인슐린 시장

제12장 호주의 비주사 인슐린 시장

제13장 인도네시아의 비주사 인슐린 시장

제14장 한국의 비주사 인슐린 시장

제15장 서유럽의 비주사 인슐린 시장

제16장 영국의 비주사 인슐린 시장

제17장 독일의 비주사 인슐린 시장

제18장 프랑스의 비주사 인슐린 시장

제19장 이탈리아의 비주사 인슐린 시장

제20장 스페인의 비주사 인슐린 시장

제21장 동유럽의 비주사 인슐린 시장

제22장 러시아의 비주사 인슐린 시장

제23장 북미의 비주사 인슐린 시장

제24장 미국의 비주사 인슐린 시장

제25장 캐나다의 비주사 인슐린 시장

제26장 남미의 비주사 인슐린 시장

제27장 브라질의 비주사 인슐린 시장

제28장 중동의 비주사 인슐린 시장

제29장 아프리카의 비주사 인슐린 시장

제30장 비주사 인슐린 시장의 경쟁 구도와 기업 개요

• 비주사 인슐린 시장의 경쟁 구도
• 비주사 인슐린 시장 기업 개요
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • Novartis AG

제31장 비주사 인슐린 시장 기타 대형 및 혁신적 기업

• Sanofi S.A
• Bristol-Myers Squibb Company
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Takeda Pharmaceutical
• Eli Lilly and Company
• Boehringer Ingelheim
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Ipsen S.A.
• Cadila Healthcare Limited
• Dr. Reddy's Laboratories Limited

제32장 세계의 비주사 인슐린 시장의 경쟁 벤치마킹과 대시보드

제33장 비주사 인슐린 시장에서의 주요 합병과 인수

제34장 비주사 인슐린 시장의 최근 동향

제35장 비주사 인슐린 시장의 잠재적 가능성이 높은 국가, 부문, 전략

• 2029년 비주사 인슐린 시장 - 가장 새로운 기회를 제공하는 국가
• 2029년 비주사 인슐린 시장 - 가장 새로운 기회를 제공하는 부문
• 2029년 비주사 인슐린 시장 - 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

KSA

영문 목차

영문목차

Non-injectable insulin, a type of insulin that doesn't require injection for administration, presents an innovative approach to diabetes management, aiming to enhance convenience and patient compliance. These non-injectable forms of insulin offer alternatives to traditional injections, potentially improving the overall quality of life for individuals with diabetes. They come in various forms, such as pills, sprays, and other delivery mechanisms, providing flexibility and ease of use for patients.

Synthetic insulin and semi-synthetic insulin are the two primary types of non-injectable insulin. Synthetic insulin is artificially produced through biotechnological methods, offering precise control over its composition and properties. This type of insulin can be tailored to meet specific patient needs and preferences. Semi-synthetic insulin is derived from natural sources but undergoes chemical modifications to enhance its stability, efficacy, or other desirable characteristics. Non-injectable insulin products are distributed through various channels, including hospital pharmacies, online pharmacies, and drug stores, ensuring accessibility for patients worldwide. These innovative insulin formulations represent a significant advancement in diabetes care, providing patients with additional options for managing their condition effectively while reducing the burden of frequent injections.

The non-injectable insulin market research report is one of a series of new reports from The Business Research Company that provides non-injectable insulin market statistics, including non-injectable insulin industry global market size, regional shares, competitors with a non-injectable insulin market share, detailed non-injectable insulin market segments, market trends and opportunities, and any further data you may need to thrive in the non-injectable insulin industry. This non-injectable insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-injectable insulin market size has grown rapidly in recent years. It will grow from $1.92 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to patient compliance improvement, addressing needle phobia, quality of life enhancement, ease of administration, and stable blood glucose control.

The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $3.17 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to continued patient compliance emphasis, persistent needle phobia solutions, further quality of life improvements, continuous safety enhancement, and reduced infection and injury risks. Major trends in the forecast period include technological advancements, evolution of technological solutions, digital health integration, nanotechnology applications, and combination therapies.

The growing prevalence of obesity and diabetes is projected to boost the growth of the non-injectable insulin market in the coming years. Obesity is defined as the excessive accumulation of body fat, typically resulting from an imbalance between calorie intake and energy expenditure, while diabetes mellitus is a collection of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin is utilized to manage diabetes and obesity, as it can improve treatment adherence by overcoming barriers to insulin therapy, potentially aid in weight management, and offer more convenient treatment alternatives. For instance, in 2022, the World Heart Federation, a Switzerland-based NGO, reported that global obesity rates are expected to rise significantly, with approximately 2.3 billion individuals, including children and adults, facing overweight and obesity in 2021, a figure projected to increase to 2.7 billion by 2025. Additionally, an April 2023 report from the British Diabetic Association, a UK-based diabetes charity, indicated that there are 4.3 million people living with diabetes in the UK, with over 2.4 million at high risk of developing type 2 diabetes. The registration figures for 2021-22 showed an increase of 148,951 compared to the prior year. Thus, the escalating issues of obesity and diabetes are driving the growth of the non-injectable insulin market.

Major companies in the non-injectable insulin market are focusing on innovative drug delivery technologies, such as needle-free oral insulin sprays, to enhance the lives of individuals managing diabetes with multiple insulin injections. Needle-free insulin sprays offer a painless alternative for regulating blood glucose levels, providing a convenient option by allowing doses to be sprayed directly into the mouth. For example, NiedlFree Technologies introduced Ozulin, an oral insulin spray, in November 2023. Ozulin aims to offer a user-friendly solution for individuals with diabetes, especially those who may struggle with traditional injectable insulin methods. If approved, Ozulin could revolutionize diabetes management by offering a more convenient and pain-free alternative to insulin injections.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition merges Abbott's proficiency in continuous glucose monitoring with Bigfoot's smart insulin management systems, bolstering Abbott's standing as a leader in comprehensive diabetes care. The acquisition aligns with Abbott's dedication to advancing connected solutions for precise diabetes management. Bigfoot Biomedical Inc., a US-based medical technology company, specializes in intelligent insulin administration systems for diabetes care.

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-injectable insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-injectable insulin market consists of sales of oral insulin, inhaled insulin, nasal insulin, carrier agents, and stabilizers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-injectable Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-injectable insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-injectable insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-injectable insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Synthetic Insulin; Semi Synthetic Insulin
• 2) By Product: Pills; Sprays; Other Products
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Drug Stores
• Subsegments:
• 1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin; Short-Acting Synthetic Insulin; Intermediate-Acting Synthetic Insulin; Long-Acting Synthetic Insulin
• 2) By Semi-Synthetic Insulin: Modified Insulin Analogs; Combination Insulins; Biosimilar Insulins; Insulin With Extended Release Formulations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-injectable Insulin Market Characteristics

3. Non-injectable Insulin Market Trends And Strategies

4. Non-injectable Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-injectable Insulin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-injectable Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-injectable Insulin Market Growth Rate Analysis
• 5.4. Global Non-injectable Insulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-injectable Insulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-injectable Insulin Total Addressable Market (TAM)

6. Non-injectable Insulin Market Segmentation

• 6.1. Global Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Insulin
• Semi Synthetic Insulin
• 6.2. Global Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pills
• Sprays
• Other Products
• 6.3. Global Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Drug Stores
• 6.4. Global Non-injectable Insulin Market, Sub-Segmentation Of Synthetic Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid-Acting Synthetic Insulin
• Short-Acting Synthetic Insulin
• Intermediate-Acting Synthetic Insulin
• Long-Acting Synthetic Insulin
• 6.5. Global Non-injectable Insulin Market, Sub-Segmentation Of Semi-Synthetic Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Modified Insulin Analogs
• Combination Insulins
• Biosimilar Insulins
• Insulin With Extended Release Formulations

7. Non-injectable Insulin Market Regional And Country Analysis

• 7.1. Global Non-injectable Insulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-injectable Insulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-injectable Insulin Market

• 8.1. Asia-Pacific Non-injectable Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-injectable Insulin Market

• 9.1. China Non-injectable Insulin Market Overview
• 9.2. China Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-injectable Insulin Market

• 10.1. India Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-injectable Insulin Market

• 11.1. Japan Non-injectable Insulin Market Overview
• 11.2. Japan Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-injectable Insulin Market

• 12.1. Australia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-injectable Insulin Market

• 13.1. Indonesia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-injectable Insulin Market

• 14.1. South Korea Non-injectable Insulin Market Overview
• 14.2. South Korea Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-injectable Insulin Market

• 15.1. Western Europe Non-injectable Insulin Market Overview
• 15.2. Western Europe Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-injectable Insulin Market

• 16.1. UK Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-injectable Insulin Market

• 17.1. Germany Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-injectable Insulin Market

• 18.1. France Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-injectable Insulin Market

• 19.1. Italy Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-injectable Insulin Market

• 20.1. Spain Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-injectable Insulin Market

• 21.1. Eastern Europe Non-injectable Insulin Market Overview
• 21.2. Eastern Europe Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-injectable Insulin Market

• 22.1. Russia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-injectable Insulin Market

• 23.1. North America Non-injectable Insulin Market Overview
• 23.2. North America Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-injectable Insulin Market

• 24.1. USA Non-injectable Insulin Market Overview
• 24.2. USA Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-injectable Insulin Market

• 25.1. Canada Non-injectable Insulin Market Overview
• 25.2. Canada Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-injectable Insulin Market

• 26.1. South America Non-injectable Insulin Market Overview
• 26.2. South America Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-injectable Insulin Market

• 27.1. Brazil Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-injectable Insulin Market

• 28.1. Middle East Non-injectable Insulin Market Overview
• 28.2. Middle East Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-injectable Insulin Market

• 29.1. Africa Non-injectable Insulin Market Overview
• 29.2. Africa Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-injectable Insulin Market Competitive Landscape And Company Profiles

• 30.1. Non-injectable Insulin Market Competitive Landscape
• 30.2. Non-injectable Insulin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-injectable Insulin Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca
• 31.4. Abbott Laboratories
• 31.5. GlaxoSmithKline
• 31.6. Takeda Pharmaceutical
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim
• 31.9. Novo Nordisk A/S
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Ipsen S.A.
• 31.14. Cadila Healthcare Limited
• 31.15. Dr. Reddy's Laboratories Limited

32. Global Non-injectable Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-injectable Insulin Market

34. Recent Developments In The Non-injectable Insulin Market

35. Non-injectable Insulin Market High Potential Countries, Segments and Strategies

• 35.1 Non-injectable Insulin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-injectable Insulin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-injectable Insulin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료